Worldwide the number of patients receiving renal replacement therapy is estimated at more than 1.4 million 1 , with incidence growing 8% annually 2 . In developing countries like Nepal, the management of ESRD is largely guided by economic considerations. While renal transplantation (RT) remains the most rational treatment for patient with end-stage renal disease, the majority of the patient with ESRD receives dialytic therapy. Hemodialysis is mainly a short-term measure to support ESRD patients and bridge the gap to transplantation. Infection is a common complication in dialysis patients and many die of septicemia related complications rather than the disease itself. In Nepal, the majority of patients starting hemodialysis die or are forced to abandon treatment because of cost.
Since the fi rst successful transplant of a kidney from one twin to another in 1954, RT has moved from being at the cutting edge to being a mature technology. Successful renal transplantation is associated with signifi cant improvement in survival as well as quality of life. Compared to prolong dialysis it is more cost effective in patient requiring long term RT. Factors that should be considered before transplantation include the adequate supply of donor organs, the side effects of treatment, co-morbid disease in recipients, and equity of access to transplantation. Among the three renal replacement therapy options available, RT is the preferred mode, as it is most cost-effective and provides a better quality of life. The successful outcomes of RT over the last fi ve decades have made RT as the optimum form of therapy for patients with CKD stage V. However, due to fi nancial constraints and non-availability of organs, only about 5% of ESRD patients undergo transplant surgery.
In developing country like Nepal, due to limited access to renal replacement therapy, the ideal approach should be to reduce the incidence of ESRD and attempt preventive measures. Data on the cost-effectiveness of intervention in CKD is lacking, however it is recognized that CKD prevention would be most cost-effective as part of an integrated strategy targeting chronic vascular diseases. 3 Multi drug regimens for the prevention of cardiovascular disease in at-risk populations have been shown to be cost effective. 4 A study in a rural part of India has shown that with an integrated intervention to achieve acceptable blood pressure and diabetes targets to lower the prevalence of CKD was obtained at an annual cost of US$ 0.43 per capita of population. 5 This model can be applied in Nepal due to geographical and socio-economic similarity. However, when already diagnosed, they need proper treatment to increase the quality of life. Shrestha et al has concluded that optimization of therapy is needed in our patient to increase the quality of life of the patients with ESRD. 6 Now when preemptive renal transplantation is in the process of getting recognition 7 , we are still far away from renal transplantation. Not only time has come, it is already late to re-start transplantation. A study has found that the economic and quality of life advantages of transplantation make it an attractive modality over dialysis, and coordinated efforts to facilitate safe and ethical transplantation in the countries with low income. 8 transplantation, leading to ambiguity on complex ethical issues and creating environments that facilitate commercial organ traffi cking. A vast number of patients going abroad and candidates who can come up with the money for transplantation at home a waiting for the day when renal transplantation will start once again and continue forever.
